Oxidative stress in the atherosclerotic process;Le stress oxydant, composante physiopathologique de l'athérosclérose

Immuno-Analyse et Biologie Specialisee

Volumn 21, Issue 3, 2006, Pages 144-150

  Beaudeux, J L ^a   Delattre, J ^a   Therond, P ^a   Bonnefont Rousselot, D ^a   Legrand, A ^a   Peynet, J ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Atherosclerosis; Lipoprotein; NADPH oxidase; Nitric oxide; Oxidative stress

Indexed keywords

ANTIOXIDANT; GROWTH FACTOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; MITOCHONDRIAL RESPIRATION; NECROSIS; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY CHAIN; RISK FACTOR;

EID: 33745713722     PISSN: 09232532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immbio.2006.02.001     Document Type: Article

References (27)

1. Witztum J.L., and Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc. Med. 11 (2001) 93-102
2. Griendling K.K., Sorescu D., Lassegue B., and Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Atheroscler. Thromb. Vasc. Biol. 20 (2000) 2175-2183
3. Peynet J., Beaudeux J.L., and Legrand A. Stress oxydant et athérosclérose. In: Delattre J., Beaudeux J.-L., Bonnefont D., and Rousselot (Eds). Radicaux libres et stress oxydant : aspects biologiques et pathologiques (2005), Tec Doc Lavoiser Ed.
4. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 138 (1999) 419-420
5. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the committee on vacular lesions of the council on atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1512-1531
6. Stary H.C. Natural history and histological classification of atherosclerotic lesions: an update. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 1177-1178
7. McGrath J.C., Deighan C., Briones A.M., Shafaroudi M.M., McBride M., Adler J., et al. New aspects of vascular remodelling: the involvement of all vascular cell types. Exp. Physiol. 90 4 (2005) 469-475
8. Beaudeux J.L., Giral P., Bruckert E., Foglietti M.J., and Chapman M.J. Matrix metalloproteniases, inflammation and atherosclerosis: therapeutic perspectives. Clim. Chem. Lab. Med. 42 (2004) 121-131
9. Beaudeux J.L., Delattre J., and Peynet J. Lipoprotéines et athérosclérose : mécanismes moléculaires et cellulaires. In: Delattre J., Durand G., and Jardillier J.C. (Eds). Biochimie pathologique : 91-107 (2003), Flammarion Médecine-Sciences, Paris
10. Spitaler M.M., and Graier W.F. Vascular targets of redox signalling in diabetes mellitus. Diabetologia 45 (2002) 476-494
11. Beaudeux J.L. Oxidative modification of lipoprotein (a): physical chemical aspects and biologic implications. Ann. Pharm. Fr. 57 (1999) 266-275
12. Steinberg D., Parthasarathy S., Carew T.E., Thoo J.G., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increases its atherogenicity. N. Engl. J. Med. 320 (1989) 915-924
13. Heinecke J.W. Mechanism of oxidative damage of low-density lipoprotein in atherosclerosis. Curr. Opin. Lipidol. 8 (1997) 268-274
14. Van Lenten B., Navab M., Shah D., Fogelman A.M., and Lusis A.J. The role of high density lipoproteins in oxidation and inflammation. Trends Cardiovasc. Med. 11 (2001) 155-161
15. Bonnefont-Rousselot D., Therond P., Peynet J., Legrand A., and Delattre J. High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis. Clin. Chem. Lab. Med. 37 (1999) 939-948
16. Meier B., Radeke H.H., and Selle S. Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumor necrosis factor-alpha. Biochem. J. 263 (1989) 519-545
17. Griendling K.K., Sorescu D., and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86 (2000) 494-501
18. Sorescu D., Szocs K., and Griendling K.K. NAD(P)H oxidases and their relevance to atherosclerosis. Trends Cardiovasc. Med. 11 (2001) 124-131
19. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Brasen J.H., and Statchkov M. Increased NADH oxidase mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99 (1999) 2027-2033
20. Tummala P., Chen X.L., Sundell C.L., Laursen J.B., Hammes P., Alexander W., et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature. A potential link between the rennin-angiotensin and atherosclerosis. Circulation 100 (1999) 1223-1229
21. Ouslimani N., Peynet J., Bonnefont-Rousselot D., Therond P., Legrand A., and Beaudeux J.L. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 54 (2005) 829-834
22. Ballinger S.W. Mitochondrial dysfunction in cardiovascular disease. Free Radic. Biol. Med. 38 (2005) 1278-1295
23. Nishikawa T., Edelstein D., Du X.L., Yamagishi S.I., Matsumara T., Kenneda Y., et al. Normalizing mitochondrial sueorxide productin blocks three pathways of hyperglycaemic damage. Nature 404 (2000) 787-790
24. Blanc M.C., Moinard C., and Cynober L. Monoxyde d'azote. In: Delattre J., Beaudeux J.L., and Bonnefont-Rousselot D. (Eds). Radicaux libres et stress oxydant : aspects biologiques et pathologiques (2005), Tec Doc Lavoisiers, Ed.
25. -ONOO. Rebounding from nitric oxide. Circ. Res. 89 (2001) 295-297
26. Hyaden M.R., and Tyagi S.C. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycaemia a late manifestation? The role of NOS, NO and redox stress. Cardiovasc. Diabetol. 2 (2003) 2-9
27. Violi F., and Cangemi R. Antioxidants ans cardiovascular disease. Curr. Opin. Investing. Drugs 6 9 (2005) 895-900